Alzheimer Europe Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2013
NCT02017340
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Alzheimer Europe

Active Ingredients

Drugs in Phase 3 Trials (1)

nivaldipine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1